|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dockets Entered
On September 9, 2004
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 2004D-0193
|
| Guidance
for Industry: Eligibility Determination for Donors of Human Cells,
Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
|
|
|
| 2004E-0413
|
| Patent Term Extension
for CIALIS (tadalafil), U.S. Patent No. 5,859, 006
|
|
|
|
|
| 2004M-0403
|
| P030025 - TAXUS Express2
Paclitaxel-Eluting Coronary Stent System (Monorail and Over-the-Wire)
|
|
|
|
|
| 2004N-0050
|
| Over-the-Counter Drug
Products; Safety and Efficacy Review; Additional Dandruff Control
Ingredient
|
|
|
|
|
| 2004N-0264
|
| Federal Measures to
Mitigate BSE Risks: Considerations for Further Action
|
|
|
|
|
| 2004D-0193
|
| Guidance for Industry:
Eligibility Determination for Donors of Human Cells, Tissues, and
Cellular and Tissue-Based Products (HCT/Ps)
|
|
|
|
|
| EC
1
|
| University of Iowa
Hospitals
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004E-0413
|
| Patent Term Extension
for CIALIS (tadalafil), U.S. Patent No. 5,859, 006
|
|
|
|
|
| APP
1
Continued
|
| ICOS Corporation
|
| Vol #:
|
| 1
|
|
|
|
|
| LET
1
|
| U.S. Patent &
Trademark Office
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004M-0403
|
| P030025 - TAXUS
Express2 Paclitaxel-Eluting Coronary Stent System (Monorail and Over-the-Wire)
|
|
|
|
|
| AAV
1
|
| Boston Scientific
Corporation
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004N-0050
|
| Over-the-Counter
Drug Products; Safety and Efficacy Review; Additional Dandruff Control
Ingredient
|
|
|
|
|
| LET
2
|
| HFD-560 to Frederick
Stearns
|
| Vol #:
|
| 2
|
|
|
|
|
| 2004N-0264
|
| Federal Measures
to Mitigate BSE Risks: Considerations for Further Action
|
|
|
|
|
| C
131
|
| Rohwer Technical Consulting,
LLC
|
| Vol #:
|
| 22
|
|
